{"id":70120,"date":"2026-07-16T18:40:40","date_gmt":"2026-07-16T10:40:40","guid":{"rendered":"https:\/\/flcube.com\/?p=70120"},"modified":"2026-07-16T18:40:41","modified_gmt":"2026-07-16T10:40:41","slug":"amoytop-biotech-secures-nmpa-clinical-trial-approval-for-act201-novel-aso-therapy-for-chronic-hepatitis-b","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70120","title":{"rendered":"Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Amoytop Biotech<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688278:SHA\">SHA: 688278<\/a>) announced today that its investigational drug <strong>ACT201<\/strong> has received <strong>clinical trial approval<\/strong> from China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> for the treatment of <strong>chronic hepatitis B<\/strong>. The innovative antisense oligonucleotide (ASO) therapy represents a novel approach to addressing one of China&#8217;s most significant public health challenges.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone-key-details\" class=\"wp-block-heading\">Regulatory Milestone | Key Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Amoytop Biotech (SHA: 688278)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>ACT201<\/td><\/tr><tr><td><strong>Regulatory Authority<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Clinical trial approval<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Chronic hepatitis B<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>July 16, 2026<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Preclinical to Phase I transition<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<h3 id=\"h-molecular-innovation\" class=\"wp-block-heading\">Molecular Innovation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Class:<\/strong> Antisense oligonucleotide (ASO) therapeutic<\/li>\n\n\n\n<li><strong>Dual Mechanism:<\/strong> Enhanced RNase H-mediated antiviral activity + moderate hTLR8 agonist activity<\/li>\n\n\n\n<li><strong>Target Specificity:<\/strong> Designed for improved liver targeting with reduced off-target effects<\/li>\n\n\n\n<li><strong>Pharmacokinetic Advantage:<\/strong> Improved liver-to-kidney distribution ratio<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-biological-rationale\" class=\"wp-block-heading\">Biological Rationale<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">ACT201 employs a sophisticated dual-mechanism approach to combat chronic hepatitis B:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>RNase H Enhancement:<\/strong> Significantly boosts RNase H-mediated degradation of viral RNA, directly targeting HBV replication<\/li>\n\n\n\n<li><strong>Immune Modulation:<\/strong> Moderate human TLR8 (hTLR8) agonist activity stimulates innate immune responses against infected hepatocytes<\/li>\n\n\n\n<li><strong>Tissue Targeting:<\/strong> Optimized distribution profile concentrates drug exposure in liver (site of HBV replication) while minimizing kidney exposure<\/li>\n\n\n\n<li><strong>Safety Profile:<\/strong> Reduced off-target effects compared to conventional ASO therapies<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-national-recognition\" class=\"wp-block-heading\">National Recognition<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The drug&#8217;s therapeutic innovation has been formally recognized through selection for the <strong>2025 National Science and Technology Major Project for Innovative Drug R&amp;D<\/strong>, highlighting its strategic importance to China&#8217;s pharmaceutical innovation agenda.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-therapeutic-need\" class=\"wp-block-heading\">Market Opportunity &amp; Therapeutic Need<\/h2>\n\n\n\n<h3 id=\"h-chronic-hepatitis-b-landscape-in-china\" class=\"wp-block-heading\">Chronic Hepatitis B Landscape in China<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence:<\/strong> Affects approximately <strong>70-80 million people<\/strong> in China (5-6% of population)<\/li>\n\n\n\n<li><strong>Current Treatment Limitations:<\/strong> Nucleos(t)ide analogues suppress but rarely cure HBV; interferon therapy has significant side effects<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Functional cure remains elusive with current standard-of-care therapies<\/li>\n\n\n\n<li><strong>Public Health Priority:<\/strong> HBV elimination is a key national health objective<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-global-market-context\" class=\"wp-block-heading\">Global Market Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Worldwide Burden:<\/strong> Over <strong>290 million people<\/strong> chronically infected globally<\/li>\n\n\n\n<li><strong>Market Size:<\/strong> Global HBV therapeutics market projected to reach <strong>$5-7 billion by 2030<\/strong><\/li>\n\n\n\n<li><strong>Competitive Gap:<\/strong> Limited pipeline of truly curative approaches beyond viral suppression<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-significance-for-amoytop-biotech\" class=\"wp-block-heading\">Strategic Significance for Amoytop Biotech<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">This clinical trial approval represents a major milestone for Amoytop&#8217;s innovative drug development capabilities:<\/p>\n\n\n\n<h3 id=\"h-technology-platform-validation\" class=\"wp-block-heading\">Technology Platform Validation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ASO Expertise:<\/strong> Demonstrates advanced oligonucleotide drug design and optimization capabilities<\/li>\n\n\n\n<li><strong>Dual-Mechanism Innovation:<\/strong> Sophisticated approach combining direct antiviral and immune-stimulating activities<\/li>\n\n\n\n<li><strong>Tissue Targeting:<\/strong> Proprietary delivery and distribution optimization technologies<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-pipeline-advancement\" class=\"wp-block-heading\">Pipeline Advancement<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lead Asset:<\/strong> ACT201 emerges as Amoytop&#8217;s flagship development candidate<\/li>\n\n\n\n<li><strong>First-in-Class Potential:<\/strong> Novel mechanism may position ACT201 as differentiated therapy in competitive landscape<\/li>\n\n\n\n<li><strong>Global Ambition:<\/strong> Strong intellectual property foundation supports international development potential<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-government-support-leverage\" class=\"wp-block-heading\">Government Support Leverage<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Selection for the <strong>National Science and Technology Major Project<\/strong> provides:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Funding Support:<\/strong> Access to government R&amp;D funding and resources<\/li>\n\n\n\n<li><strong>Regulatory Priority:<\/strong> Expedited review pathways and regulatory guidance<\/li>\n\n\n\n<li><strong>Strategic Recognition:<\/strong> Validation of ACT201&#8217;s importance to national health priorities<\/li>\n\n\n\n<li><strong>Partnership Opportunities:<\/strong> Enhanced credibility for academic and industry collaborations<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-differentiation\" class=\"wp-block-heading\">Competitive Differentiation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">ACT201&#8217;s unique positioning in the HBV therapeutic landscape includes:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Dual Mechanism Advantage:<\/strong> Combines direct antiviral activity with immune stimulation, potentially enabling functional cure<\/li>\n\n\n\n<li><strong>Improved Safety Profile:<\/strong> Enhanced liver targeting reduces systemic exposure and potential toxicity<\/li>\n\n\n\n<li><strong>Novel Target Approach:<\/strong> ASO mechanism offers different resistance profile compared to nucleos(t)ide analogues<\/li>\n\n\n\n<li><strong>Chinese Innovation Leadership:<\/strong> Represents cutting-edge domestic pharmaceutical innovation in high-priority disease area<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">If successful in clinical development, ACT201 could become one of the first <strong>dual-mechanism ASO therapies<\/strong> approved for chronic hepatitis B, establishing Amoytop Biotech as a leader in next-generation antiviral therapeutics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory approvals, and market opportunities. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688278_20260716_R9TM.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688278_20260716_R9TM.\"><\/object><a id=\"wp-block-file--media-e9874908-7f8c-4796-8540-1f7d908ef5d4\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688278_20260716_R9TM.pdf\">688278_20260716_R9TM<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688278_20260716_R9TM.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e9874908-7f8c-4796-8540-1f7d908ef5d4\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Amoytop Biotech (SHA: 688278) announced today that its investigational drug ACT201 has received clinical trial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[470,62,64,1232,89],"class_list":["post-70120","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-amoytop-biotech","tag-clinical-trial-approval-initiation","tag-rnai-aso","tag-sha-688278","tag-viral-hepatitis"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Amoytop Biotech (SHA: 688278) announced today that its investigational drug ACT201 has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of chronic hepatitis B. The innovative antisense oligonucleotide (ASO) therapy represents a novel approach to addressing one of China&#039;s most significant public health challenges.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70120\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B\" \/>\n<meta property=\"og:description\" content=\"Amoytop Biotech (SHA: 688278) announced today that its investigational drug ACT201 has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) for the treatment of chronic hepatitis B. The innovative antisense oligonucleotide (ASO) therapy represents a novel approach to addressing one of China&#039;s most significant public health challenges.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70120\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T10:40:40+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T10:40:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70120#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70120\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B\",\"datePublished\":\"2026-07-16T10:40:40+00:00\",\"dateModified\":\"2026-07-16T10:40:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70120\"},\"wordCount\":618,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Amoytop Biotech\",\"Clinical trial approval \\\/ initiation\",\"RNAi \\\/ ASO\",\"SHA: 688278\",\"Viral hepatitis\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70120#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70120\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70120\",\"name\":\"Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-16T10:40:40+00:00\",\"dateModified\":\"2026-07-16T10:40:41+00:00\",\"description\":\"Amoytop Biotech (SHA: 688278) announced today that its investigational drug ACT201 has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of chronic hepatitis B. The innovative antisense oligonucleotide (ASO) therapy represents a novel approach to addressing one of China's most significant public health challenges.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70120#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70120\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70120#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B - Insight, China&#039;s Pharmaceutical Industry","description":"Amoytop Biotech (SHA: 688278) announced today that its investigational drug ACT201 has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of chronic hepatitis B. The innovative antisense oligonucleotide (ASO) therapy represents a novel approach to addressing one of China's most significant public health challenges.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70120","og_locale":"en_US","og_type":"article","og_title":"Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B","og_description":"Amoytop Biotech (SHA: 688278) announced today that its investigational drug ACT201 has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of chronic hepatitis B. The innovative antisense oligonucleotide (ASO) therapy represents a novel approach to addressing one of China's most significant public health challenges.","og_url":"https:\/\/flcube.com\/?p=70120","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-16T10:40:40+00:00","article_modified_time":"2026-07-16T10:40:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70120#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70120"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B","datePublished":"2026-07-16T10:40:40+00:00","dateModified":"2026-07-16T10:40:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70120"},"wordCount":618,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Amoytop Biotech","Clinical trial approval \/ initiation","RNAi \/ ASO","SHA: 688278","Viral hepatitis"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70120#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70120","url":"https:\/\/flcube.com\/?p=70120","name":"Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-16T10:40:40+00:00","dateModified":"2026-07-16T10:40:41+00:00","description":"Amoytop Biotech (SHA: 688278) announced today that its investigational drug ACT201 has received clinical trial approval from China's National Medical Products Administration (NMPA) for the treatment of chronic hepatitis B. The innovative antisense oligonucleotide (ASO) therapy represents a novel approach to addressing one of China's most significant public health challenges.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70120#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70120"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70120#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Amoytop Biotech Secures NMPA Clinical Trial Approval for ACT201, Novel ASO Therapy for Chronic Hepatitis B"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70120","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70120"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70120\/revisions"}],"predecessor-version":[{"id":70122,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70120\/revisions\/70122"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70120"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70120"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70120"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}